India, Nov. 13 -- This week's biotech roundup features a series of regulatory approvals across obesity, stroke prevention, oncology, and medical devices, alongside workforce reductions and cost-cutting measures at several companies. Major partnerships, acquisitions and licensing agreements reshaped pipeline and commercial strategies, while clinical trial updates brought positive results in autoimmune diseases, gene therapy and cardiovascular risk reduction, alongside setbacks in inflammatory diseases.
This roundup also highlights broader healthcare developments, including new drug safety warnings, and emerging COVID-19 variants.
Read on...
Approvals
InspireMD Wins FDA Nod for TCAR Stent
InspireMD (NSPR) received FDA approval for its CG...